GGrantIndex
← Leaderboards

Huntington Potter

University Of Colorado Denver

Google Scholar ↗PubMed ↗ORCID ↗
$11,515,934
Attributed
$15,748,551
Total exposure
8
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.8M · FY2005–25
$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$23,998,080 · 9

By mechanism

R01$11,895,946 · 5
P50$8,317,864 · 2
RF1$2,601,812 · 1
R61$1,182,458 · 1

Top collaborators

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposS DiseaseNeuronsAmyloid Beta-Protein PrecursorMouse ModelPathogenesisAmyloid Beta-ProteinDefectBrainCognitionS Disease ModelCognitive DeficitsCellsRecombinantsPathologyApolipoprotein EBloodInflammationAffectFollow-UpGlial Fibrillary Acidic ProteinMicrotubulesMutantAstrocytes

Grant awards (31)

Neurovascular unit dysfunction in Down syndrome revealed by TBI$738,140
R01 · FY2025 · NS
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease$2,599,447
R01 · FY2023 · AG · contact PI
Neurovascular unit dysfunction in Down syndrome revealed by TBI$2,601,812
RF1 · FY2022 · NS
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease$2,326,177
R01 · FY2022 · AG · contact PI
GM-CSF/sargramostim treatment to improve cognition in Down syndrome$836,914
R61 · FY2022 · AG · contact PI
Phase II trial of GM-CSF/sargramostim in Alzheimer's Disease$1,340,244
R01 · FY2021 · AG · contact PI
GM-CSF/sargramostim treatment to improve cognition in Down syndrome$345,544
R61 · FY2021 · AG · contact PI
Neuronal dysfunction caused by Abeta inhibition of MT motors$321,563
R01 · FY2015 · NS · contact PI
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD$309,211
R01 · FY2015 · AG · contact PI
Neuronal dysfunction caused by Abeta inhibition of MT motors$318,348
R01 · FY2014 · NS · contact PI
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD$317,750
R01 · FY2014 · AG · contact PI
Neuronal dysfunction caused by Abeta inhibition of MT motors$310,308
R01 · FY2013 · NS · contact PI
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD$299,305
R01 · FY2013 · AG · contact PI
Neuronal dysfunction caused by Abeta inhibition of MT motors$321,563
R01 · FY2012 · NS · contact PI
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD$304,446
R01 · FY2012 · AG · contact PI
Neuronal dysfunction caused by Abeta inhibition of MT motors$321,563
R01 · FY2011 · NS · contact PI
Abnormal Low Density Lipoprotein Receptor Localization and Function in AD$303,441
R01 · FY2011 · AG · contact PI
Florida Alzheimer's Disease Research$875,000
P50 · FY2010 · AG · contact PI
Florida Alzheimer's Disease Research$1,502,923
P50 · FY2009 · AG · contact PI
Florida Alzheimer's Disease Research$1,470,501
P50 · FY2008 · AG · contact PI
Florida Alzheimer's Disease Research$1,467,542
P50 · FY2007 · AG · contact PI
Florida Alzheimer's Disease Research$1,459,431
P50 · FY2006 · AG · contact PI
Florida Alzheimer's Disease Research$1,435,913
P50 · FY2005 · AG
ADMINISTRATIVE CORE$68,335
P50 · FY2005 · AG
Florida Alzheimer's Disease Research$38,219
P50 · FY2005 · AG
PROMOTERS AN INHIBITORS OF ALZEIMER AMYLOID FORMATION$445,484
R01 · FY2004 · AG
PROMOTERS AN INHIBITORS OF ALZEIMER AMYLOID FORMATION$294,630
R01 · FY2003 · AG
Promoters and Inhibitors of Alzheimer Amyloid Formation$204,263
R01 · FY2003 · AG
PROMOTERS AN INHIBITORS OF ALZEIMER AMYLOID FORMATION$283,846
R01 · FY2002 · AG
PROMOTERS AN INHIBITORS OF ALZEIMER AMYLOID FORMATION$273,283
R01 · FY2001 · AG
PROMOTERS AN INHIBITORS OF ALZEIMER AMYLOID FORMATION$262,934
R01 · FY2000 · AG